NEW YORK, December 25, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors in Treace Medical Concepts, Inc. (“Treace” or the “Company”) TMCI. Those investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, extension 7980.

The investigation concerns whether Treace and certain of its officers and/or directors have engaged in securities fraud or other illegal business practices.

[Click here for information about joining the class action]

On November 15, 2022, Culper Research published a brief report on Treace (the “Culper Report”). The Culper report expressed the “view that Treace’s primary innovation was not any medical advances, but rather aggressive reimbursement practices and deceptive DTC marketing,” which the Culper report called “as problematic and self-defeating as the Insurers appear to have begun scrutinizing reimbursements for lapoplasty procedures as customer complaints mount about misleading claims made by Treace.”

As a result of this news, Treace’s stock price fell $3.57 per share, or 14.81%, to close at $20.54 per share on November 15, 2022.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris and Tel Aviv, is recognized as one of the leading law firms specializing in corporate, securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, best known as Dean of the Class Bar Association, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues the tradition he founded and fights for the rights of victims of securities fraud, fiduciary breaches and corporate wrongdoing. The firm has recovered numerous multi-million dollar claims on behalf of group members. See www.pomlaw.com.

CONTACT:
Robert S Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980